Skip to content
DataLookout
Menu

NCT06589778

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 10, 2024 to Sep 27, 2024
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determination of Recommended Phase II dose (RP2D)
Timeframe: From first dose of study treatment until the end of Cycle 1(up to 21 days)
Objective Response Rate (ORR)
Timeframe: From time of first dose of SHR-A2102 or Adebrelimab or SHR-8068 until the date of objective disease progression or death (up to 12 months)
Incidence and severity of AEs
Timeframe: The observation period ended at the end of the 21-day period after the first dose of SHR-A2102 or Adebrelimab or SHR-8068 (up to 21 days)

Secondary (4)

Disease Control Rate (DCR)
Duration of Response (DoR)
Progression free Survival (PFS)
Overall Survival (OS)

Arms and interventions

SHR-A2102 in Combination with Adebrelimab and SHR-8068Experimental

Drugs: SHR-A2102, Adebelimab (SHR-1316), SHR-8068

Sites

1 site in 1 country

  • Shanghai Chest HospitalShanghai, Shanghai Municipality, China